<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03820336</url>
  </required_header>
  <id_info>
    <org_study_id>18-0639</org_study_id>
    <nct_id>NCT03820336</nct_id>
  </id_info>
  <brief_title>Cardiovascular Effects of EVOO in Healthy Reproductive-aged Women</brief_title>
  <official_title>Cardiovascular Effects of Extra Virgin Olive Oil (EVOO) in Healthy Reproductive-aged Women: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Vermont Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Vermont Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to compare changes in cardiovascular function and markers of inflammation and
      metabolic dysfunction in women randomized to treatment with extra virgin olive oil (EVOO)
      versus those randomized to treatment with a control oil low in oleic acid and phenols for 8
      weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will be randomized to receive 45 ml (40 g) of extra virgin olive oil (EVOO)
      daily for 8 weeks or an identical dose of a control sunflower seed oil low in oleic acid and
      phenol content. EVOO high in oleic acid and phenolic content will be identified and shipped
      from Italy and stored protected from heat and light in the Bionutrition Core at the Clinical
      Research Center at the University of Vermont Medical Center. Women will undergo a detailed
      cardiovascular assessment at baseline and following treatment, including assessment of blood
      pressure, pulse-wave velocity, calculation of arterial distensibility and beta stiffness,
      flow-mediated vasodilation, cardiac output, response to volume challenge and dual-energy
      X-ray absorptiometry (DEXA). Lipid profiles and markers of inflammation, oxidative stress and
      metabolic dysfunction will also be assessed at both study visits.

      Investigators hypothesize that treatment with high oleic acid and phenolic EVOO will be
      associated with decreased blood pressure, improved vascular compliance and blood vessel
      function, and with improvement in lipid profile, inflammation and markers of metabolic
      dysfunction.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2019</start_date>
  <completion_date type="Anticipated">February 2020</completion_date>
  <primary_completion_date type="Anticipated">February 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Arterial pulse wave velocity</measure>
    <time_frame>8 weeks</time_frame>
    <description>Arterial pulse wave velocity in meters/second. This is an index of vessel stiffness.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>8 weeks</time_frame>
    <description>Blood pressure in millimeters mercury (mm Hg).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Arterial distensibility</measure>
    <time_frame>8 weeks</time_frame>
    <description>Arterial distensibility (no units). This is an index of vessel stiffness.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Arterial Beta Stiffness Index</measure>
    <time_frame>8 weeks</time_frame>
    <description>Arterial Beta Stiffness Index (no units). This is an index of vessel stiffness.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Flow-mediated vasodilation</measure>
    <time_frame>8 weeks</time_frame>
    <description>Flow-mediated vasodilation in percent. This is a measure of endothelial health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac output</measure>
    <time_frame>8 weeks</time_frame>
    <description>Cardiac output in liters per minute.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac output response to volume challenge</measure>
    <time_frame>8 weeks</time_frame>
    <description>Cardiac output response to volume challenge in liters per minute. This is a measure of vascular compliance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein</measure>
    <time_frame>1 year</time_frame>
    <description>Serum C-reactive protein in milligrams/liter. This is a marker of inflammation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High Density Lipoprotein (HDL) Cholesterol</measure>
    <time_frame>1 year</time_frame>
    <description>Serum high density lipoprotein in milligrams/deciliter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low Density Lipoprotein (LDL) Cholesterol</measure>
    <time_frame>1 year</time_frame>
    <description>Serum low density lipoprotein in milligrams/deciliter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides</measure>
    <time_frame>1 year</time_frame>
    <description>Serum triglycerides in milligrams/deciliter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin</measure>
    <time_frame>1 year</time_frame>
    <description>Fasting serum insulin level in micro international units per milliliter (µIU/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin A1C</measure>
    <time_frame>1 year</time_frame>
    <description>Serum hemoglobin A1C in percent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>B-type natriuretic peptide (BNP)</measure>
    <time_frame>1 year</time_frame>
    <description>B-type natriuretic peptide (BNP) in picograms per milliliter. This is a measure of cardiac function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin 6 (IL-6)</measure>
    <time_frame>1 year</time_frame>
    <description>Interleukin 6 in picograms per milliliter. This is a measure of inflammation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor necrosis factor alpha (TNF-α)</measure>
    <time_frame>1 year</time_frame>
    <description>Tumor necrosis factor alpha in picograms per milliliter. This is a measure of inflammation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Hypertension</condition>
  <condition>Vascular Stiffness</condition>
  <arm_group>
    <arm_group_label>Extra Virgin Olive Oil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Oil</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Extra Virgin Olive Oil</intervention_name>
    <description>Subjects will consume 45 ml (40 g) of EVOO daily for 8 weeks.</description>
    <arm_group_label>Extra Virgin Olive Oil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Control Oil</intervention_name>
    <description>Subjects will consume 45 ml (40 g) of a control sunflower seed oil daily for 8 weeks.</description>
    <arm_group_label>Control Oil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women are eligible to participate if they are between the ages of 18 and 40, in good
             health, with regular menstrual cycles and no prior pregnancies.

        Exclusion Criteria:

          -  Routinely take medications or supplements known to affect blood pressure, heart or
             blood vessel function, or those with anti-inflammatory or antioxidant properties

          -  Smoking

          -  Pregnancy

          -  Other conditions that would impair adherence, such as allergy to olive oil or
             sunflower oil or difficulty swallowing
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erin A Morris, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Vermont Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Erin Morris, MD</last_name>
    <phone>(802) 847-0408</phone>
    <email>erin.morris@uvmhealth.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lorinda Roberts</last_name>
    <phone>(802) 656-5711</phone>
    <email>lorinda.roberts@uvmhealth.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Vermont Medical Center</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin A Morris, MD</last_name>
      <phone>802-847-0408</phone>
      <email>erin.morris@uvmhealth.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>January 23, 2019</study_first_submitted>
  <study_first_submitted_qc>January 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2019</study_first_posted>
  <last_update_submitted>April 15, 2019</last_update_submitted>
  <last_update_submitted_qc>April 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Vermont Medical Center</investigator_affiliation>
    <investigator_full_name>Erin Morris</investigator_full_name>
    <investigator_title>Assistant Professor, Maternal-Fetal Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

